Berry Oncology and MGI Tech Collaborate for Cancer Early Screening Solutions in China

On March 27, Berry Oncology and MGI Tech signed a strategic cooperation agreement. The two parties will focus on localizing and converting the sequencing platform for the core product pipeline of full-cycle cancer precision diagnosis and treatment, as well as introducing an automation platform and registering cancer early screening and drug companion testing products. They will also carry out all-round strategic cooperation in other fields, working together to create precise cancer diagnosis and treatment with independent scientific and technological innovation strength, particularly in the Chinese plan for early cancer screening.

As leading companies in the fields of early screening technology and sequencing equipment, Berry Oncology and MGI Tech will collaborate to enhance the commercialization of early cancer screening products by optimizing their performance, cost-effectiveness, and accessibility.

en_GBEnglish (UK)